Supply of transcatheter heart valves (TAVI) to Maastricht UMC+

Summary

The tender concerns the supply of transcatheter aortic valve replacement products and related accessories for Maastricht UMC+’s Heart and Vascular Centre, including training and clinical support where required. The estimated volume is approximately 220 sets per year, with forecast growth of around 5% annually; this volume is indicative and the authority provides no purchase or turnover guarantee. Framework agreements will be awarded to up to four suppliers, with indicative shares of approximately 40%, 35%, and a combined 15% for the third and fourth suppliers; the remaining 10% may be used for special clinical cases, studies, or other products. Tenders must be submitted digitally in the required formats by 9 November 2026 at 08:00. Total cost of ownership price accounts for 30% and quality for 70%; the minimum quality score is 280 out of 700 points, or 40%. The initial contract term is three years, with three possible one-year extensions, for a maximum term of six years.